Pressrelease November 12, 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING IN Genovis AB (PUBL)

The shareholders in Genovis AB (publ), reg. no. 556574-5345, with its registered office in Kävlinge municipality, Skåne County (the "Company"), are hereby given notice that the Extraordinary General Meeting will be held on Tuesday 8 December 2026 at 12.00 CET at the Company's premises, Karl Johans väg 104, Kävlinge, Sweden. Registration of voting rights starts at 11.30 CET and will stop when the Meeting opens.

Shareholders who wish to exercise their voting rights at the Extraordinary General Meeting must:

- be recorded in the share register maintained by Euroclear Sweden AB ("**Euroclear**") on Monday 30 November 2026; and
- give notice to the Company of their intention to attend the Meeting according to the instructions under the heading "Notification of attendance in person or by proxy", no later than Wednesday 2 December 2026.

Nominee-registered shares

Shareholders whose shares are nominee-registered through a bank or other authorised depositary, for example in a custody account, must – in addition to giving notice of their attendance – request that the shares be temporarily re-registered in their own name so that the shareholder is registered in Euroclear's share register as of the record date on Monday 30 November 2026. Re-registration may be temporary (so-called voting rights registration) and is requested from the nominee in advance in accordance with the nominee's routines. Voting right registration that the shareholder has requested and has been issued by the nominee no later than Wednesday 2 December 2026 will be accepted in the preparation of the share register.

Please observe that this procedure may also apply for shares that are held in a bank's custody account and on certain Swedish investment savings accounts (ISK).

Notification of attendance in person or by proxy

Shareholders who wish to attend the Extraordinary General Meeting in person or by proxy must notify the Company of this no later than Wednesday 2 December 2026

- by e-mail to **theo.bistrom@lindahl.se**; or
- by post to Advokatfirman Lindahl KB, Att: Theo Biström, "Extraordinary General Meeting", Box 1203, 751 42 Uppsala.

In the notification, provide your name or company name, personal or organisation ID number, address, phone number and, if applicable, the number of persons attending with you (maximum two).

Shareholders represented by a proxy or representative should send authorisation documents (a power of attorney and/or registration certificate) to the Company at the above postal address well in advance of the Extraordinary General Meeting and preferably no later than Wednesday 2 December 2026. Power of attorney forms are available on the Company's website, **https://investor.genovis.com/en/corporate-governance/general-meeting/**.

Personal data

Personal data obtained from the share register, notices of attendance at the Extraordinary General Meeting and information on proxies will be used for registration, preparation of the voting list for the Meeting and, where applicable, the minutes of the Meeting.

For information about how your personal data is processed, please refer to the Privacy Policy available on Euroclear's website:

https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Proposed agenda

1. Opening of the Meeting and election of the Chairman of the Meeting
2. Establishment and approval of the voting list
3. Approval of the agenda
4. Election of one or two persons to attest the minutes
5. Determination as to whether the Meeting has been duly convened
6. Resolution on authorisation for the Board to resolve on repurchases and transfers of own shares
7. Closing of the Meeting

Resolution proposals

Election of the Chairman of the Meeting (agenda item 1)

It is proposed that attorney in law Arne Källén be elected Chairman of the Meeting or, in the event of their absence, the person appointed by the Board instead.

Resolution on authorisation for the Board to resolve on repurchases and transfers of own shares (agenda item 6)

The 2026 Annual General Meeting resolved to authorise the Board to resolve on repurchases and transfers of own shares, conditional upon the legislative proposal in Government Bill 2025/26:125 being adopted and entering into force. The Swedish Parliament adopted the legislative amendment on 20 May 2026. For the sake of good order, the Board considers that the matter should be submitted to the shareholders again at a General Meeting held after the legislative amendment has entered into force.

The Board proposes that the Extraordinary General Meeting authorises the Board to resolve, on one or more occasions during the period up to the next Annual General Meeting, on repurchases and transfers of own shares on the following terms.

Repurchases of shares may be made on Nasdaq First North Growth Market in accordance with the Nasdaq First North Growth Market Rulebook for Issuers of Shares. The maximum number of own shares that may be repurchased shall be such that the Company's holding of own shares does not at any time exceed ten (10) per cent of all shares in the Company. Repurchases of shares may only be made at a price per share within the price range prevailing for the share on Nasdaq First North Growth Market at the relevant time. Repurchases shall be made against cash payment.

Transfers may be made of all own shares held by the Company at the time of the Board's resolution on a transfer. Transfers of own shares on Nasdaq First North Growth Market may only be made at a price per share within the price range prevailing for the share on Nasdaq First North Growth Market at the relevant time. Transfers of own shares other than on Nasdaq First North Growth Market shall be made against cash payment, payment in kind or set-off, and the price shall be determined so that the transfer is made on market terms. Transfers of own shares other than on Nasdaq First North Growth Market may be made with deviation from shareholders' pre-emption rights.

The purpose of a repurchase or transfer of own shares, and the reason for any transfer with deviation from shareholders' pre-emption rights, shall be to enable the adaptation and improvement of the Company's capital structure, thereby contributing to increased shareholder value, and to take advantage of strategic business opportunities by financing such opportunities wholly or partly with own shares.

This resolution replaces the authorisation regarding repurchases and transfers of own shares granted to the Board by the 2026 Annual General Meeting.

Shares

At the time of the issue of this notice, the total number of shares in the Company amounts to 67,458,379, each carrying one vote.

Majority requirements

A valid resolution under agenda item 6 above requires the support of shareholders representing at least two thirds of both the votes cast and the shares represented at the Meeting.

Documentation

The Board's complete proposal is included in this notice. The proposal, power of attorney forms and other documents required under the Swedish Companies Act will be available at the Company at Karl Johans väg 104, Kävlinge, and on the Company's website, **www.genovis.com**, from 17 November 2026. The documents will be sent free of charge to shareholders who request them and provide their postal address.

The documents will also be available at the Extraordinary General Meeting.

Information at the Extraordinary General Meeting

The Board and Managing Director shall, if requested by any shareholder and if the Board considers that it can be done without causing material harm to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda.

Shareholders who wish to submit questions in advance may do so by post to Genovis AB, Att: Legal, Box 4, 244 21 Kävlinge or by e-mail to **legal@genovis.com.**

_____

Kävlinge, November 2026

Genovis AB (publ)

The Board

Contacts
Fredrik Olsson, CEO
Tel: +46 (0)70-276 46 56 **fredrik.olsson@genovis.com**

About Us
Headquartered in Kävlinge, Sweden, Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis' innovative products and technologies are used by scientists all over the world and the product formats streamline and improve workflows in biochemical analysis and sequencing, as well as in the development, quality control and manufacturing of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiaries Genovis Inc. (US), SEQURNA AB and KPL ApS. Genovis shares are listed on Nasdaq First North Growth Market and DNB Carnegie Investment Bank AB is the Company's Certified Adviser.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.